Rankings
▼
Calendar
VRDN Q4 2023 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
VRDN
Viridian Therapeutics, Inc.
$3B
Q4 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$72,000
-31.4% YoY
Gross Profit
$72,000
100.0% margin
Operating Income
-$71M
-99275.0% margin
Net Income
-$67M
-92861.1% margin
EPS (Diluted)
$-1.35
QoQ Revenue Growth
+0.0%
Cash Flow
Operating Cash Flow
-$38M
Free Cash Flow
-$38M
Stock-Based Comp.
$26M
Balance Sheet
Total Assets
$490M
Total Liabilities
$48M
Stockholders' Equity
$442M
Cash & Equivalents
$103M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$72,000
$105,000
-31.4%
Gross Profit
$72,000
-$39M
+100.2%
Operating Income
-$71M
-$49M
-45.7%
Net Income
-$67M
-$46M
-46.0%
← FY 2023
All Quarters
Q1 2024 →